Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2008-05-13
2008-05-13
Meller, Michael (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Reexamination Certificate
active
11682505
ABSTRACT:
A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease to production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme.Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as “CYP2A6” for brevity) is predictive of an individual who: (i) has a decreased risk of becoming a smoker, (ii) will smoke less if he/she becomes dependent, and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6-mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analysing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.
REFERENCES:
patent: 5653987 (1997-08-01), Modi et al.
patent: 5760049 (1998-06-01), Viner
patent: 6908631 (2005-06-01), Sellers et al.
patent: 2002/0019421 (2002-02-01), Biberman
patent: 2002/0168403 (2002-11-01), Biberman
patent: 2005/0032844 (2005-02-01), Sellers
patent: WO9004387 (1990-05-01), None
patent: WO9503050 (1995-02-01), None
patent: WO9534679 (1995-12-01), None
Berkman, et al., “In Vitro-In Vivo Correlations of Human (S)-Nicotine Metabolism”, Biochemical Pharmacology, vol. 50, No. 4. pp. 565-570, 1995, Pergamon, Mar. 6, 1995.
Cashman, et al., “Metabolism of Nicotine by Human Liver Microsomes: Stereoselective Formation of trans-Nicotine N′-Oxide”, Chem. Res. Toxicol, 1992, 5, 639-646, 1992.
Fernandez-Salguero, et al. “A Genetic Polymorphism in Coumarin 7-Hydroxylation: Sequence of the Human CYP2A Genes and Identification of Variant CYP2A6 Alleles”, Am J. Hum. Genet. 57:651-660, Jun. 1, 1995.
McCracken, et al., “Cotinine Formation by cDNA-expressed Human Cytochromes P450”, Med. Sci. Rev., 1992, 20, 877-878.
Seaton, et al., “Variable Affecting Nicotine Metabolism”, Pharmac. Ther. vol. 60, pp. 461-500, Pergamon, 1993.
Fowler, et al., “Brain Monoamine Oxidase A Inhibition in Cigarette Smokers”, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 14065-14069, Nov. 1996.
Tiano, et al., “Human CYP2A6 Activation of 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): Mutational Specificity in gpt Gene of AS52 Cells”, Carcinogenesis, vol. 15, No. 12, pp. 2859-2866, 1984.
J. Invest. Med, vol. 44, No. 1, p. 120A, 1996.
Notice of Opposition to a European Patent, Patent No. 1033979B1 to Nicogen Inc.
Zhang, W. et al., “Specificity and Selectivity of Tranylcypromine and Methoxsalen Inhibition of Cytochrome P450s in Vitro”, http://www.utoronto.ca/grdpharm/zhang.html, May 20, 1999.
Tyndale, R.F. et al., “Inhibition of Nicotine's Metabolism: A Potential New Treatment for Tobacco Dependence”, Clinical Pharmaceology & Therapeutics, vol. 65, No. 2, p. 145: Ol-A-1, 1999.
Sellers, E.M. et al. “Inhibition of CYP2A6 Decreases Smoking”, Clinical Pharmacology & Therapeutics, vol. 65, No. 2, p. 153: PI1-26. 1999.
Sellers, E.M. et al., “Mimicking Gene Defects to Treat Drug Dependence”, Annals of the New York Academy of Sciences, (2000) 909:233-246.
Draper, A.J. et al., “Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver Microsomes”, Archives of Biochemistry and Biophysics, (1997) vol. 341, No. 1, pp. 47-61.
Chauret, N. et al., “In Vitro Comparison of Cytochrome P450-Mediated Metabolic Activities in Human, Dog, Cat and Horse”, Drug Metabolism and Disposition, vol. 25, No. 10.
George, T.P. et al., “A Preliminary Placebo-Controlled Trial of Selegiline Hydrochloride for Smoking Cessation”, 2003, Biol. Psychiatry, vol. 53, pp. 136-143.
Fowler, J.S. et al., “Inhibition of Monoamine Oxidase B in the Brains of Smokers”, 1996, Nature, vol. 379, pp. 733-736.
Nakajima, M. et al., “Characterization of CYP2A6 Involved in 3′-hydroxylation of Continine in Human Liver Microsomes”, J. Pharmacol. Exp. Therap., (1996) vol. 277, No. 2, pp. 1010-1015.
Nakajima, M. et al., “Role of Human Cytochrome P4502A6 in C-oxidation of Nicotine”, Drug Metabol. Dospos., (1996) vol. 24, No. 11, pp. 1212-1217.
Tsujimoto, A et al., “Potent Inhibitory Action of Pilocarpine on Hepatic Drug Metabolism”, Jpn. J. Pharmacol., (1972) vol. 22, No. 5, 736.
Tsujimoto, A. et al., “A Study of the Nature of Pilocarpine on Hepatic Drug-Metabolizing Enzymes”, Biochem. Pharmacol., (1977) vol. 26, No. 21, pp. 2072-2074.
Foth, H. et al., “Nicotine Metabolism is Isolated Perfused Lung and Liver of Phenobarbital and Benzoflavone-Treated Rats”, Arch. Toxicol., (1991) vol. 65, No. 1, pp. 68-72.
Kyerematen, G. A., et al., “Metabolism of Nicotine by Hepatocytes”, Biochem. Pharmacol., (1990) vol. 40, No. 8, pp. 1747-1756.
Yamazaki, H. et al., “Cytochrome P450 sE1 and 2A6 Enzymes as Major Catalysts for Metabolic Activation of N-nitrosodialkylamines and Tobacco-Related Nitorsamines in Human Liver Microsomes”, Carcinogenesis (1992) vol. 13, No. 10, pp. 1789-1794.
CAPLUS, DN 120:238085, Gamitskij et al., SU 1803032 A1, Mar. 23, 1993, English abstract with notes from oral translation.
Mays et al., “Methoxsalen is a Potent Inhibitor of Caffeine in Humans”, Clin. Pharmacol. Ther., 42:621-626 (1987).
Maenpaa et al., “Metabolic Interactions of methoxsalen and Coumarin in Humans and Mice”, Biochem. Pharmacol., 48(7), (1994), 1363-9.
Benowitz, N.L. et al., “Deficient C-Oxidationof Nicotine”, Clinical Pharmacol. and Therap., 57(5):590-594 (1995) (Abstract).
Sellers Edward
Tyndale Rachel
Bereskin & Parr
Folkins Patricia
Meller Michael
Nicogen, Inc.
LandOfFree
Therapeutic and diagnostic methods dependent on CYP2A enzymes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic methods dependent on CYP2A enzymes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic methods dependent on CYP2A enzymes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3938840